| Insideraktier | 5 420 108 shares |
Insider Sentiment Score
Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.
Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.
Uppdateringsfrekvens: Dagligen
Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.
Office Sentiment Score
Officersentiment Score hittar företag som köps av Corporate Officers.
Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.
Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.
Uppdateringsfrekvens: Dagligen
Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.
Viktiga insidernyckeltal
Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.
Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).
Nettoantalet insiders som köper (rankning)
N/A
Nettoantalet insiders som köper är den totala mängden insiders som säljer minus det totala antalet insiders som säljer under de senaste 90 dagarna. Percentilrankningen visas här (intervall från 0 till 100%).
Procent av flytande köpta av insiders (ranking)
N/A
Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.
Insiderhandelsdiagram
Aeglea BioTherapeutics Inc insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.
Insiderlista och lönsamhetsstatistik
Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.
See our leaderboard of most profitable insider traders.
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|
Report errors via our new Insider Auditing Tool
Track Records av insiderköp - Kortsiktig vinstanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i AGLE / Aeglea BioTherapeutics Inc. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Track Records av insiderförsäljning - Kortsiktig förlustanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i AGLE / Aeglea BioTherapeutics Inc. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Transaktionshistorik
Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.
| Fil datum |
Handel datum |
Schema | Insider | Ticker | Värdepappertitel | Kod | Direkta | Utövningspris | Enhet pris |
Enheter ändrad |
Värde ändrad (1K) |
Kvarvarande Optioner |
Kvarvarande Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-03 | 2025-09-02 | 4 | Burrows Scott L | SYRE | Common Stock | D | 16,2600 | −18 428 | −300 | 97 994 | ||||
| 2025-01-14 | 2025-01-10 | 4 | HENDERSON MICHAEL THOMAS | SYRE | Common Stock | D | 105 379 | 105 379 | ||||||
| 2024-11-08 | 2024-11-06 | 4 | Albers Jeffrey W. By Sessions LLC | SYRE | Common Stock | I | 36,7631 | −6 700 | −246 | 27 360 | ||||
| 2024-10-28 | 2024-10-25 | 4 | Albers Jeffrey W. By Sessions LLC | SYRE | Common Stock | I | 36,4300 | −300 | −11 | 34 060 | ||||
| 2024-09-05 | 2024-09-03 | 4 | Burrows Scott L | SYRE | Common Stock | D | 28,1730 | −18 531 | −522 | 116 422 | ||||
| 2024-04-25 | 2024-04-25 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Fund II L.P. | SYRE | Common Stock | I | 3 639 680 | 4 018 101 | ||||||
| 2024-02-20 | 2024-02-15 | 4 | Turtle Cameron | SYRE | Common Stock | D | 9,8200 | 400 | 4 | 746 907 | ||||
| 2023-12-29 | 2023-12-29 | 4 | Fairmount Funds Management LLC By Tomas Kiselak | SYRE | Common Stock | I | 406 038 | 406 038 | ||||||
| 2023-12-29 | 2023-12-29 | 4 | Fairmount Funds Management LLC By Peter Harwin | SYRE | Common Stock | I | 406 038 | 406 038 | ||||||
| 2023-12-29 | 2023-12-29 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Co-Invest L.P. | SYRE | Common Stock | I | −3 435 480 | 0 | ||||||
| 2023-12-22 | 2023-12-22 | 4 | Burrows Scott L | SYRE | Common Stock | D | 134 953 | 134 953 | ||||||
| 2023-12-08 | 2023-11-24 | 4/A | Albers Jeffrey W. By Sessions LLC | SYRE | Common Stock | I | 34 360 | 34 360 | ||||||
| 2023-11-28 | 2023-11-24 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Co-Invest L.P. | AGLE | Common Stock | I | 3 435 480 | 3 435 480 | ||||||
| 2023-11-27 | 2023-11-24 | 4 | Turtle Cameron | AGLE | Common Stock | D | 723 440 | 746 507 | ||||||
| 2023-06-30 | 3 | Turtle Cameron | AGLE | Common Stock | D | 576 699 | ||||||||
| 2023-06-30 | 3 | Fairmount Funds Management LLC By Fairmount Healthcare Fund II LP | AGLE | Common Stock | I | 9 184 458 | ||||||||
| 2023-06-30 | 3 | Fairmount Funds Management LLC By Fairmount Healthcare Fund LP( | AGLE | Common Stock | I | 276 082 | ||||||||
| 2023-01-27 | 3 | Neuman Linda L | AGLE | Common Stock | D | 4 000 | ||||||||
| 2022-08-25 | 3 | Kastenmayer James Paul | AGLE | Common Stock | D | 4 000 | ||||||||
| 2022-08-25 | 2022-08-25 | 4 | Souza Marcio | AGLE | Common Stock | D | 0,5608 | 90 000 | 50 | 90 000 | ||||
| 2022-06-10 | 2022-06-08 | 4 | Hanley Jr. Michael Conick | AGLE | Common Stock | D | 0,7100 | 28 200 | 20 | 36 200 | ||||
| 2022-03-18 | 2022-03-16 | 4 | Quinn Anthony | AGLE | Common Stock | D | 2,3440 | 80 079 | 188 | 550 540 | ||||
| 2022-03-15 | 2022-03-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 1,8611 | 42 417 | 79 | 473 461 | ||||
| 2022-03-15 | 2022-03-14 | 4 | Quinn Anthony | AGLE | Common Stock | D | 1,9300 | 67 472 | 130 | 431 044 | ||||
| 2022-03-15 | 2022-03-11 | 4 | Quinn Anthony | AGLE | Common Stock | D | 2,0640 | 34 777 | 72 | 363 572 | ||||
| 2022-03-15 | 2022-03-11 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 2,0800 | 75 000 | 156 | 165 372 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 350 000 | 350 000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Weber Steven | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 30 000 | 30 000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 180 000 | 180 000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 160 000 | 160 000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Alspaugh Jonathan | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 170 000 | 170 000 | |||||
| 2022-02-14 | 2021-10-20 | 5 | Quinn Anthony | AGLE | Common Stock | I | 10 000 | 208 845 | ||||||
| 2022-02-14 | 2021-10-20 | 5 | Quinn Anthony | AGLE | Common Stock | D | −10 000 | 328 795 | ||||||
| 2022-02-14 | 2021-10-18 | 5 | Quinn Anthony | AGLE | Common Stock | I | 23 809 | 208 845 | ||||||
| 2022-02-14 | 2021-10-18 | 5 | Quinn Anthony | AGLE | Common Stock | D | −23 809 | 328 795 | ||||||
| 2022-02-14 | 2021-10-14 | 5 | Quinn Anthony | AGLE | Common Stock | I | 175 036 | 208 845 | ||||||
| 2022-02-14 | 2021-10-14 | 5 | Quinn Anthony | AGLE | Common Stock | D | −175 036 | 328 795 | ||||||
| 2022-02-14 | 2018-12-28 | 5 | Quinn Anthony | AGLE | Common Stock | I | 57 450 | 57 450 | ||||||
| 2022-02-14 | 2018-12-28 | 5 | Quinn Anthony | AGLE | Common Stock | D | −57 450 | 328 795 | ||||||
| 2021-12-13 | 2021-12-13 | 4 | Shanafelt Armen | AGLE | Common Stock | D | 3,6500 | 14 685 | 54 | 150 000 | ||||
| 2021-12-13 | 2021-12-10 | 4 | Shanafelt Armen | AGLE | Common Stock | D | 3,6500 | 13 516 | 49 | 135 315 | ||||
| 2021-12-13 | 2021-12-09 | 4 | Shanafelt Armen | AGLE | Common Stock | D | 3,6680 | 121 799 | 447 | 121 799 | ||||
| 2021-12-13 | 2021-12-10 | 4 | Quinn Anthony | AGLE | Common Stock | D | 3,7500 | 10 526 | 39 | 328 795 | ||||
| 2021-12-13 | 2021-12-09 | 4 | Quinn Anthony | AGLE | Common Stock | D | 3,7000 | 43 108 | 159 | 318 269 | ||||
| 2021-12-13 | 2021-12-09 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 3,7200 | 50 000 | 186 | 90 372 | ||||
| 2021-11-16 | 2021-11-12 | 4 | Smith Hunter C | AGLE | Director Stock Option (right to buy) | D | 7,04 | 60 000 | 60 000 | |||||
| 2021-08-18 | 2021-08-18 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 6,7222 | 7 200 | 48 | 40 372 | ||||
| 2021-08-18 | 2021-08-17 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 6,4973 | 23 392 | 152 | 33 172 | ||||
| 2021-08-18 | 2021-08-16 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 6,3676 | 9 780 | 62 | 9 780 | ||||
| 2021-07-08 | 2021-07-06 | 4 | Alspaugh Jonathan | AGLE | Employee Stock Option (right to buy) | D | 7,03 | 160 000 | 160 000 | |||||
| 2021-06-22 | 2021-06-18 | 4 | Souza Marcio | AGLE | Director Stock Option (right to buy) | D | 6,44 | 60 000 | 60 000 | |||||
| 2021-06-10 | 2021-06-08 | 4 | BAKER BROS. ADVISORS LP See Footnotes | AGLE | Non-Qualified Stock Option (right to buy) | I | 6,80 | 40 000 | 40 000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40 000 | 40 000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40 000 | 40 000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40 000 | 40 000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40 000 | 40 000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Lawton Alison Frances | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40 000 | 40 000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40 000 | 40 000 | |||||
| 2021-02-25 | 3 | BAKER JULIAN See Footnotes | AGLE | Common Stock | I | 3 094 590 | ||||||||
| 2021-02-25 | 3 | BAKER JULIAN See Footnotes | AGLE | Common Stock | I | 315 516 | ||||||||
| 2021-02-25 | 2021-02-23 | 4 | BAKER BROS. ADVISORS LP See Footnotes | AGLE | Non-Qualified Stock Option (right to buy) | I | 7,11 | 47 200 | 47 200 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Weber Steven | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 50 000 | 50 000 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 160 000 | 160 000 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 330 000 | 330 000 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 135 000 | 135 000 | |||||
| 2021-02-08 | 3 | Weber Steven | AGLE | Common Stock | D | 17 652 | ||||||||
| 2020-12-17 | 2020-12-15 | 4 | Lawton Alison Frances | AGLE | Director Stock Option (right to buy) | D | 9,09 | 47 200 | 47 200 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28 100 | 28 100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28 100 | 28 100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28 100 | 28 100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28 100 | 28 100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28 100 | 28 100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28 100 | 28 100 | |||||
| 2020-05-04 | 2020-04-30 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,7500 | 165 000 | 784 | 538 469 | ||||
| 2020-02-19 | 2020-02-14 | 4 | Rao Madduri Ravin | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 25 000 | 25 000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 100 000 | 100 000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 126 000 | 126 000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 25 000 | 25 000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 301 000 | 301 000 | |||||
| 2019-11-04 | 2019-11-01 | 4 | Rao Madduri Ravin | AGLE | Employee Stock Option (right to buy) | D | 8,24 | 130 000 | 130 000 | |||||
| 2019-10-23 | 2019-10-21 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 7,79 | 130 000 | 130 000 | |||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 6,31 | −17 603 | 119 914 | |||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 5,46 | −662 | 0 | |||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 17 603 | 111 | 371 908 | ||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 662 | 4 | 354 305 | ||||
| 2019-06-14 | 2019-06-14 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,2311 | 5 282 | 33 | 353 643 | ||||
| 2019-06-14 | 2019-06-13 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,1666 | 14 406 | 89 | 348 361 | ||||
| 2019-06-14 | 2019-06-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,1148 | 12 217 | 75 | 333 955 | ||||
| 2019-06-07 | 2019-06-07 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12 400 | 12 400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12 400 | 12 400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12 400 | 12 400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12 400 | 12 400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12 400 | 12 400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12 400 | 12 400 | |||||
| 2019-05-22 | 2019-05-22 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,8596 | 3 809 | 26 | 321 738 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,8857 | 13 794 | 95 | 317 929 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,5550 | 8 989 | 59 | 304 135 | ||||
| 2019-05-17 | 2019-05-17 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,6477 | 6 218 | 41 | 295 146 | ||||
| 2019-05-17 | 2019-05-16 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,8280 | 5 520 | 38 | 288 928 | ||||
| 2019-05-17 | 2019-05-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,7566 | 6 256 | 42 | 283 408 | ||||
| 2019-05-17 | 2019-02-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 7,0980 | 719 | 5 | 277 152 | ||||
| 2019-03-08 | 2019-03-06 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 8,06 | 36 000 | 36 000 | |||||
| 2019-03-01 | 2019-02-28 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 8,36 | 280 000 | 280 000 | |||||
| 2019-03-01 | 2019-02-28 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 8,36 | 60 000 | 60 000 | |||||
| 2019-03-01 | 2019-02-28 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 8,36 | 50 200 | 50 200 | |||||
| 2019-03-01 | 2019-02-28 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 8,36 | 87 600 | 87 600 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 6,31 | −7 433 | 137 517 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 5,46 | −1 323 | 662 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 7 433 | 47 | 276 433 | ||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 1 323 | 7 | 269 000 | ||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 6,31 | −18 584 | 144 950 | |||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 5,46 | −3 306 | 1 985 | |||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 4,11 | −150 000 | 0 | |||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 18 584 | 117 | 267 677 | ||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 3 306 | 18 | 249 093 | ||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,1100 | 150 000 | 616 | 245 787 | ||||
| 2018-12-10 | 2018-08-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 9,1300 | 994 | 9 | 95 787 | ||||
| 2018-12-10 | 2018-02-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,0200 | 2 000 | 12 | 94 793 | ||||
| 2018-09-28 | 2018-09-27 | 4 | Schuchart Aaron | AGLE | Common Stock | D | 9,5000 | −5 900 | −56 | 2 500 | ||||
| 2018-09-28 | 2018-09-27 | 4 | Schuchart Aaron | AGLE | Common Stock | D | 9,5500 | −100 | −1 | 8 400 | ||||
| 2018-08-21 | 2018-08-17 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 3,50 | −8 500 | 91 500 | |||||
| 2018-08-21 | 2018-08-17 | 4 | Schuchart Aaron | AGLE | Common Stock | D | 3,5000 | 8 500 | 30 | 8 500 | ||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 4,73 | −20 000 | 10 000 | |||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 7,28 | −17 333 | 6 667 | |||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Common Stock | D | 4,7300 | 20 000 | 95 | 175 861 | ||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Common Stock | D | 7,2800 | 17 333 | 126 | 155 861 | ||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 50 000 | 50 000 | |||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 75 000 | 75 000 | |||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 75 000 | 75 000 | |||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 300 000 | 300 000 | |||||
| 2018-07-17 | 2018-07-13 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 8,78 | 36 800 | 36 800 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 6,31 | −14 866 | 163 534 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 7,04 | −24 000 | 0 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 14 866 | 94 | 92 793 | ||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 7,0400 | 24 000 | 169 | 77 927 | ||||
| 2018-07-13 | 2018-07-11 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 5,46 | −3 307 | 5 291 | |||||
| 2018-07-13 | 2018-07-11 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 3 307 | 18 | 53 927 | ||||
| 2018-06-08 | 2018-06-07 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18 400 | 18 400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18 400 | 18 400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18 400 | 18 400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18 400 | 18 400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18 400 | 18 400 | |||||
| 2018-05-14 | 2018-05-11 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,0600 | −19 550 | −197 | 2 175 314 | ||||
| 2018-05-11 | 2018-05-10 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,1300 | −22 725 | −230 | 2 194 864 | ||||
| 2018-05-11 | 2018-05-09 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,1100 | −51 230 | −518 | 2 217 589 | ||||
| 2018-05-09 | 2018-05-08 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,0300 | −26 557 | −266 | 2 268 819 | ||||
| 2018-05-09 | 2018-05-07 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,1100 | −15 548 | −157 | 2 295 376 | ||||
| 2018-03-26 | 2018-03-22 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 10,50 | 36 800 | 36 800 | |||||
| 2018-02-22 | 2018-02-20 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 20 000 | 20 000 | |||||
| 2018-02-22 | 2018-02-20 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 178 400 | 178 400 | |||||
| 2018-02-22 | 2018-02-20 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 92 100 | 92 100 | |||||
| 2018-02-22 | 2018-02-20 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 45 000 | 45 000 | |||||
| 2018-02-20 | 2018-02-15 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 5,46 | −15 211 | 8 598 | |||||
| 2018-02-20 | 2018-02-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 15 211 | 83 | 50 620 | ||||
| 2017-12-08 | 2017-12-08 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,0650 | 600 | 3 | 35 409 | ||||
| 2017-12-08 | 2017-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9882 | 2 800 | 14 | 34 809 | ||||
| 2017-12-08 | 2017-12-06 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9248 | 4 888 | 24 | 32 009 | ||||
| 2017-12-05 | 2017-12-01 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30 000 | 30 000 | |||||
| 2017-12-05 | 2017-12-01 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30 000 | 30 000 | |||||
| 2017-12-05 | 2017-12-01 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30 000 | 30 000 | |||||
| 2017-12-05 | 2017-12-05 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9310 | 5 065 | 25 | 27 121 | ||||
| 2017-12-05 | 2017-12-04 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9804 | 7 956 | 40 | 22 056 | ||||
| 2017-12-05 | 2017-12-01 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,5312 | 4 100 | 19 | 14 100 | ||||
| 2017-12-05 | 2017-12-01 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30 000 | 30 000 | |||||
| 2017-12-05 | 2017-12-05 | 4 | York Charles N II | AGLE | Common Stock | D | 4,7554 | 10 241 | 49 | 34 787 | ||||
| 2017-12-05 | 2017-12-04 | 4 | York Charles N II | AGLE | Common Stock | D | 4,9699 | 3 259 | 16 | 24 546 | ||||
| 2017-12-05 | 2017-12-01 | 4 | York Charles N II | AGLE | Common Stock | D | 4,5931 | 6 500 | 30 | 21 287 | ||||
| 2017-12-05 | 2017-08-15 | 4 | York Charles N II | AGLE | Common Stock | D | 2,5160 | 1 959 | 5 | 14 787 | ||||
| 2017-12-05 | 2017-02-15 | 4 | York Charles N II | AGLE | Common Stock | D | 4,2840 | 2 000 | 9 | 12 828 | ||||
| 2017-12-05 | 2016-08-15 | 4 | York Charles N II | AGLE | Common Stock | D | 3,9870 | 2 000 | 8 | 10 828 | ||||
| 2017-09-01 | 2017-08-31 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 4,11 | 150 000 | 150 000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Rowlinson Scott W | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 25 000 | 25 000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 10 000 | 10 000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | TYLER JOSEPH E | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 25 000 | 25 000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 10 000 | 10 000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 165 000 | 165 000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 58 500 | 58 500 | |||||
| 2017-06-20 | 2017-06-16 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 3,50 | 100 000 | 100 000 | |||||
| 2017-04-25 | 2017-04-21 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 7,04 | 24 000 | 24 000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | TYLER JOSEPH E | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 39 000 | 39 000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 90 000 | 90 000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | Hebel Henry | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 38 200 | 38 200 | |||||
| 2017-03-22 | 2017-03-20 | 4 | Lowe David George | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 160 000 | 160 000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | Rowlinson Scott W | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 60 000 | 60 000 | |||||
| 2017-02-21 | 2017-02-21 | 4 | ORBIMED ADVISORS LLC See Footnotes | AGLE | Common Stock | I | 5,3600 | 7 000 | 38 | 1 469 524 | ||||
| 2017-02-21 | 2017-02-17 | 4 | ORBIMED ADVISORS LLC See Footnotes | AGLE | Common Stock | I | 5,1900 | 71 800 | 373 | 1 462 524 | ||||
| 2017-02-21 | 2017-02-16 | 4 | ORBIMED ADVISORS LLC See Footnotes | AGLE | Common Stock | I | 5,0400 | 30 500 | 154 | 1 390 724 | ||||
| 2017-02-16 | 2017-02-15 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 5,04 | 82 000 | 82 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 7,28 | 10 000 | 10 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Lowe David George | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 160 000 | 160 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 7,28 | 10 000 | 10 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | TYLER JOSEPH E | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 33 000 | 33 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 55 000 | 55 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Rowlinson Scott W | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 47 000 | 47 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 7,28 | 24 000 | 24 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Hebel Henry | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 43 000 | 43 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Rojas-Caro Sandra | AGLE | Employee Stock Option | D | 7,28 | 200 000 | 200 000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 7,28 | 24 000 | 24 000 | |||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2 720 448 | ||||||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2 720 448 | ||||||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2 720 448 | ||||||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2 720 448 | ||||||||
| 2016-04-14 | 3/A | Shanafelt Armen by fund | AGLE | Common Stock | I | 57 619 | ||||||||
| 2016-04-14 | 2016-04-12 | 4/A | LILLY ELI & CO by fund | AGLE | Common Stock | I | 2 010 924 | 2 068 543 | ||||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Series B Preferred Stock | I | 0,00 | −1 120 448 | 0 | |||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Series A Preferred Stock | I | 0,00 | −890 476 | 0 | |||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Common Stock | I | 10,0000 | 500 000 | 5 000 | 2 568 543 | ||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Common Stock | I | 2 010 924 | 2 068 543 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Cox Russell J. | AGLE | Common Stock | D | 10,0000 | 7 000 | 70 | 7 000 | ||||
| 2016-04-12 | 2016-04-12 | 4 | Lowe David George By trust | AGLE | Series B Preferred Stock | I | 0,00 | −2 801 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Lowe David George By trust | AGLE | Series A Preferred Stock | I | 0,00 | −2 857 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Lowe David George By trust | AGLE | Common Stock | I | 5 658 | 5 658 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Series B Preferred Stock | D | 0,00 | −1 120 448 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Series A Preferred Stock | D | 0,00 | −890 476 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,0000 | 300 000 | 3 000 | 2 310 924 | ||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 2 010 924 | 2 010 924 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 10,0000 | 10 000 | 100 | 10 000 | ||||
| 2016-04-12 | 2016-04-12 | 4 | TYLER JOSEPH E | AGLE | Series B Preferred Stock | D | 0,00 | −8 403 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | TYLER JOSEPH E | AGLE | Series A Preferred Stock | D | 0,00 | −22 857 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | TYLER JOSEPH E | AGLE | Common Stock | D | 31 260 | 42 428 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II By IRA | AGLE | Series B Preferred Stock | I | 0,00 | −2 037 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II By IRA | AGLE | Series A Preferred Stock | I | 0,00 | −9 523 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II | AGLE | Series B Preferred Stock | D | 0,00 | −1 324 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II By IRA | AGLE | Common Stock | I | 11 560 | 11 560 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II | AGLE | Common Stock | D | 1 324 | 8 828 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Rowlinson Scott W By trust | AGLE | Series B Preferred Stock | I | 0,00 | −11 204 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Rowlinson Scott W By trust | AGLE | Common Stock | I | 11 204 | 11 204 | ||||||
| 2016-04-06 | 3 | Shanafelt Armen By fund | AGLE | Common Stock | I | 115 238 | ||||||||
| 2016-04-06 | 3 | Shanafelt Armen By fund | AGLE | Common Stock | I | 115 238 | ||||||||
| 2016-04-06 | 3 | Rowlinson Scott W | AGLE | Common Stock | D | 33 498 | ||||||||
| 2016-04-06 | 3 | Rowlinson Scott W | AGLE | Common Stock | D | 33 498 | ||||||||
| 2016-04-06 | 3 | TYLER JOSEPH E | AGLE | Common Stock | D | 22 336 | ||||||||
| 2016-04-06 | 3 | TYLER JOSEPH E | AGLE | Common Stock | D | 22 336 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE By trust | AGLE | Common Stock | I | 514 480 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE | AGLE | Common Stock | D | 547 532 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE Held by GMA Technologies L.L.C. | AGLE | Common Stock | I | 574 004 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE By trust | AGLE | Common Stock | I | 514 480 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE | AGLE | Common Stock | D | 547 532 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE Held by GMA Technologies L.L.C. | AGLE | Common Stock | I | 574 004 | ||||||||
| 2016-04-06 | 3 | Lowe David George | AGLE | Common Stock | D | 412 764 | ||||||||
| 2016-04-06 | 3 | Lowe David George | AGLE | Common Stock | D | 412 764 | ||||||||
| 2016-04-06 | 3 | York Charles N II | AGLE | Common Stock | D | 15 008 | ||||||||
| 2016-04-06 | 3 | York Charles N II | AGLE | Common Stock | D | 15 008 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115 238 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115 238 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115 238 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115 238 |
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)
